I. MODIFIED AGREEMENTS | ||||
Biotech Co.* (Symbol) | Pharma Co. (Country) | Change from original agreement | Disclosed Funding (M) | Terms/Details (Date) |
3-Dimensional Pharmaceuticals Inc. (DDDP) | Bristol-Myers Squibb Co. | Increase in Bristol-Myers' commitment to purchase ThermoFluor high-through-put screening workstations from three to seven, as well as the removal of a non-exclusive license to 3DP's protein expression/refolding technology and a nonexclusive licence to 3DP's GPCR structural genomics database | $4.5 | The modification will result in the return of $4.5M to Bristol-Myers of the $23.5M in up-front fees (12/18) |
Abgenix Inc. (ABGX) | Pfizer Inc. | Expanded agreement adding 10 antigen targets to the 8-year human antibody collaboration | ND | The alliance now has the potential to produce 15 product candidates; Abgenix receives an undisclosed fee to extend the agreement begun in December 1997 and originally worth $30M (1/9) |
Aradigm Corp. (ARDM) | SmithKline Beecham plc (UK) | Renegotiation of rights to the AERx Pain Management System | ND | Aradigm will assume full control and responsibility for conducting Phase IIb and later trials (12/14) |
Arena Pharmaceuticals Inc. (ARNA) | Taisho Pharmaceutical Inc. (Japan) | Expanded agreement giving Taisho worldwide rights to Arena's 18F obesity program | ND | Arena will license rights to its GPCR18F in return for an up-front payment, milestone payments and full-time equivalent payments and royalties (1/31) |
ArQule Inc. (ARQL) | Solvay Pharmaceuticals Inc. | Extended 1995 agreement providing Solvay with access to ArQule's Compass Array libraries and continued use of ArQule's Directed Assay program | ND | ArQule will receive delivery fees, research payments, milestone payments and royalties from sales; agreement is extended through 2003 (1/24) |
Aurora Biosciences Corp. (ABSC) | The R.W. Johnson Pharmaceutical Research Institute (unit of Johnson & Johnson) | Agreement to expand access to Aurora's ion channel technology platform | ND | Original agreement was made in May 2000; Aurora will provide additional instrumentation, voltage sensing probes and ongoing scientific and technical support to PRI scientists (1/4) |
Corixa Corp. (CRXA) | N.V. Organon (the Netherlands) | Amended agreement to include continued development of the recombinant form of Corixa's AnergiX.RA complex for treatment of rheumatoid arthritis | ND | The companies will share the project's costs through Phase II, and share profits from product sales (1/3) |
Cytoclonal Pharmaceutics Inc. (CYPH) | Bristol-Myers Squibb Co. | Extended research and development agreement for new technology based on microbial fermentation for the production of novel taxane therapeutics, as well as paclitaxel | $2 | The extension to the 1998 agreement involves payments of $2M in research support to Cytoclonal (1/11) |
Inflazyme Pharmaceuticals Ltd. (Canada; TSE:IZP) | Aventis Pharma AG (Germany) | Expanded collaboration for research and development of anti-inflammatories from Inflazyme's IPL576 series of small molecules | $75 | The agreement, begun in 1999, will now include IPL550,260 and IPL512,602; Inflazyme already received $16M from the initial deal and may receive up to an additional $75M; terms of the expansion were ND (1/23) |
MediChem Life Sciences Inc. (MCLS) | AstraZeneca plc (UK) | Expanded and renewed collaboration for synthetic libraries and novel method development discoveries | ND | MediChem will provide AstraZeneca with the libraries and discoveries to advance its drug discovery programs (2/21) |
Microcide Pharmaceuticals Inc. (MCDE) | The R.W. Johnson Pharmaceutical Research Institute and Ortho McNeil Pharmaceutical Inc. (units of Johnson & Johnson) | Amended research and license agreement to cover preclinical research by Microcide to develop orally active cephalosporin | ND | Microcide will receive an up-front fee and one year of funding, as well as milestone payments and royalties (1/9) |
Neurogen Corp. (NRGN) | Pfizer Inc. | Extended research collaboration for gamma-aminobutryic acid | $2.9 | The extension is the fifth since the collaboration began in 1992 and will bring Neurogen $2.9M in funding (1/4) |
Organogenesis Inc. (AMEX:ORG) | Novartis AG (Switzerland) | Amended agreement for a 1996 deal involving Apligraf | $20 | Organogenesis will receive higher royalty payments for Apligraf and will sell Novartis up to $20M in equity over the next three years (2/26) |
Rigel Pharmaceuticals Inc. (RIGL) | Pfizer Inc. | Extended asthma/allergy research collaboration for another year | ND | Pfizer will provide additional research funding and milestone payments (1/25) |
Telik Inc. (TELK) | Sanwa Kagaku Kenkyusho Co. Ltd. (Japan) | Extension of a research collaboration to use TRAP chemogenomics drug discovery technology to identify and optimize compounds for disease targets in inflammatory disorders and diabetes | $2.25 | Agreement calls for a $2.25M research payment to Telik; Telik retains U.S. rights and Sanwa has rights to commercialize active compounds resulting from the collaboration in Asia (2/6) |
Teva Pharmaceutical Industries Ltd. (Israel; TEVA) | H. Lundbeck A/S (Denmark) | Extended collaboration to include the oral formulation of Copaxone | ND | The CORAL study of Copaxone is the largest clinical study ever initiated for multiple sclerosis patients (2/14) |
Versicor Inc. (VERS) | Pharmacia Corp. | Expanded collaboration for discovery and development of oxazolidinones | $30 | Original $30M agreement dates to April 1999; Pharmacia will expand its financial support by 30% (1/3) |
ViroPharma Inc. (VPHM) | Sanofi-Synthelabo (France) | Revised agreement for pleconaril, a drug for the common cold | ND | The renegotiation reduces royalty rates due to Sanofi for U.S. and Canadian sales of pleconaril after selection of a co-promotion partner; it also eliminates milestone payment requirements for ViroPharma; ViroPharma also will take increased intellectual property rights to pleconaril in exchange for a 4.6% equity stake, about 750,000 shares, in ViroPharma by Sanofi (2/27) |
II. TERMINATED AGREEMENTS | ||||
Biotech Co.* (Symbol) | Pharma Co. (Country) | Change from original agreement | Disclosed Funding (M) | Terms/Details (Date) |
Geron Corp. (GERN) | Pharmacia Corp. | Terminated agreement for telomerase inhibitors | $58 | Companies decided to discontinue the alliance formed in 1997 (then with Pharmacia & Upjohn) and worth $58M (I/25) |
Gilead Sciences Inc. (GILD) | GlaxoSmithKline plc (UK) | Terminated agreement for exclusive worldwide rights to NX 211 | ND | GlaxoSmithKline returned all rights to Gilead per U.S. Federal Trade Commission instruction and so the merger between Glaxo Wellcome plc and Smith-Kline Beecham could be completed (1/16) |
NOTES | ||||
# The information in the chart does not cover agreements between biotech companies or agricultural agreements. | ||||
* Private companies are indicated with an asterisk; unless otherwise noted, stock symbols listed are on the NASDAQ market. | ||||
** Denotes the date the item ran in BioWorld International. | ||||
ND = Not disclosed, reported and/or available | ||||
AMEX = American Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over The Counter Bulletin Board; TSE = Toronto Stock Exchange | ||||
